cyclo

Cyclo(-RGDfK) is a potent and selective inhibitor of integrin αvβ3 with IC50 of 0.94 nM. Cyclo specifically targets tumor microvasculature and cancer cells by binding to αvβ3 integrin on the cell surface.

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

Cyclo(-RGDyC)acetate is an integrin avb3-affine polypeptide, a circular RGDyc sequence. 

Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3.

Cyclo(L-Leu-L-Pro) is a compound from Pseudomonas sesquiterpenes BC42 that exhibits antifungal activity, inhibiting fungal pathogens, the proliferation of Aspergillus flavus, conidial germination, and conidial formation, making it useful for agricultural biocontrol.

Cyclo(L-Pro-L-Val), a 2,5-diketopiperazine extracted from the fruits of Mycobacterium chiliolyticum AZ2 and Mycobacterium leprae, possesses anti-inflammatory activity and virulence activity against phytopathogenic microorganisms (e.g., R. fascians LMG 3605) and inhibits Gram-positive plant pathogens.Cyclo(L-Pro-L-Val) significantly inhibited IKKα phosphorylation and IκBα and NF-κB activation as well as iNOS and COX-2 activation in a concentration Cyclo(L-Pro-L-Val) significantly inhibited the phosphorylation of IKKα, IKKβ, IκBα, and NF-κB, as well as the activation of iNOS and COX-2 in a concentration-dependent manner, and is a potential therapeutic agent for the treatment of inflammation-related diseases.

Cyclo-L-Trp-L-Trp is a broad-spectrum antifungal. It also induces a high degree of acetylation of histones.

DOTA-cyclo(RGDfK) is a and DOTA-like chelator peptide consisting of a dimer of the peptide cross-linker DOTA and the cyclic peptide RGDFK, which preferentially targets the αvβ3 integrin receptor expressed on tumor cell membranes, allowing for the preparation of radionuclide coupled compounds (RDCs) and their use in cancer diagnostics and therapy.

Cyclo(L-Phe-L-Val) is a metabolite of the sponge bacterium Pseudoalteromonas sp. NJ6-3-1, capable of autoinducing the production of antibacterial substances active against S. aureus at low cell density. It induces neurite outgrowth and branching of chick cortical neurons in vitro at concentrations of 16 and 32 μM, increases phosphorylation of the PI3K substrate Akt, and this induction can be blocked by the PI3K inhibitor LY294002. Additionally, it enhances axon sprouting of calcitonin gene-related protein positive (CGRP+) primary afferents in the spinal cord post-crush injury and of serotonin neurons in the uninjured spinal cord. Cyclo(L-Phe-L-Val) is also a bitter taste component of cocoa and roasted coffee.

Cyclo(Gly-Gln) is a cyclic dipeptide.

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

Cyclo(RLsKDK) (BK-1361) serves as a targeted inhibitor of the metalloproteinase ADAM8, demonstrating efficacy with an IC50 value of 182 nM. This compound shows promise for use in the treatment of inflammatory diseases and cancer, highlighting its potential therapeutic applications.

Cyclo(his-pro) is an endogenous cyclic dipeptide that exerts oxidative damage protection by selectively activating the transcription factor Nrf2 signalling pathway.

TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor targeting HIF-1 heterodimerization to mitigate hypoxia signaling within cancer cells. It effectively disrupts the protein-protein interaction between HIF-1α and HIF-1β, with an inhibitory concentration (IC 50) of 1.3 μM [1].

Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor with antitumor properties, used in acute myeloid leukemia research [1].

Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.

Cyclo(RGDfC) TFA (Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA) is a cyclic pentapeptide, a cyclic RGD polypeptide with high affinity for αvβ3, which is capable of disrupting cellular integrin interactions. Cyclo(RGDfC) TFA inhibits pluripotent gene expression in embryonic stem cells (ESCs) and inhibits tumorigenic potential of mESCs in vivo. Cyclo(RGDfC) TFA inhibits the tumorigenic potential of mESC. Cyclo(RGDfC) TFA can be used for tumor-related studies.

SYNV-cyclo(CGGYF), a C5 autoinducing peptide from Staphylococcus hominis (S. hominis), demonstrates inhibitory effects on Staphylococcus aureus (S. aureus) activity. This compound shows promise in research focused on addressing S. aureus-mediated epithelial damage and inflammation [1].

SYNV-cyclo(CGGYF) TFA, a C5 autoinducing peptide derived from Staphylococcus hominis (S. hominis), demonstrates inhibition of S. aureus activity, holding potential for research into S. aureus-mediated epithelial damage and inflammation [1].

Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective antagonist of the RGD peptide, with potential applications in pulmonary arterial hypertension research [1].

Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist used in cancer research [1].

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

Cyclo(RGDyC), a cyclic pentapeptide, exhibits anti-angiogenic properties and has been investigated in conjunction with liposomal delivery systems for the study of ocular neovascular diseases and cancer [1] [2].